Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: A multicenter study

Masaru Takeuchi, Takeshi Kezuka, Sunao Sugita, Hiroshi Keino, Kenichi Namba, Toshikatsu Kaburaki, Kazuichi Maruyama, Kei Nakai, Kuniaki Hijioka, Etsuko Shibuya, Keiko Komae, Junko Hori, Nobuyuki Ohguro, Koh Hei Sonoda, Nobuhisa Mizuki, Annabelle A. Okada, Tatsuro Ishibashi, Hiroshi Goto, Manabu Mochizuki

Research output: Contribution to journalArticlepeer-review

100 Citations (Scopus)


Purpose: To evaluate the long-term efficacy and safety of infliximab for the treatment of uveitis in Behçet's disease (BD).

Design: Retrospective multicenter study using a questionnaire.

Participants: A total of 164 consecutive patients with BD treated with infliximab for more than 1 year were studied. The mean age at initiation of infliximab treatment was 42.6±11.7 years, and the mean treatment duration was 32.9±14.4 months.

Methods: Data before and at the last visit during infliximab treatment were analyzed in 4 groups divided by duration of treatment: group A (n = 43, 12-<24 months), group B (n = 62, 24-<36 months), group C (n = 42, 36-<48 months), and group D (n = 17, ≥48 months).

Main Outcome Measures: Best-corrected visual acuity (BCVA), relapse of ocular inflammation, numbers of ocular inflammatory attacks per year, and adverse effects of infliximab therapy.

Results: The frequency of ocular attacks decreased in all groups (from 5.3±3.0 to 1.0±0.3 in group A, 4.8±4.6 to 1.4±0.3 in group B, 4.1±2.9 to 0.9±0.3 in group C, and 9.5±5.8 to 1.6±0.5 in group D; all P < 0.05). The BCVA was improved in approximately 55% of the eyes after treatment. Mean BCVA converted to logarithm of the minimum angle of resolution was improved after treatment with infliximab in groups A to C (from 0.79±1.04 to 0.59±0.94 in group A, 0.59±1.07 to 0.41±1.04 in group B, and 1.15±1.77 to 0.92±1.73 in group C; all P < 0.05) but not in group D. Uveitis relapsed in 59.1% of all patients after infliximab treatment, and no difference in duration until relapse was observed between individual groups. Approximately 80% of relapses occurred within 1 year after the initiation of infliximab treatment in all groups, 90% of which were controlled by increasing doses of topical corticosteroids and shortening the interval of infliximab infusion. Adverse effects were observed in 65 cases or 35% of all subjects. Infliximab treatment was continued in 85% of the patients, but 15% of the patients discontinued infliximab treatment because of adverse effects or insufficient efficacy.

Conclusions: Infliximab reduced the frequency of ocular attacks and improved visual acuity in patients with BD-related uveitis and was generally well tolerated with few serious adverse events.

Original languageEnglish
Pages (from-to)1877-1884
Number of pages8
Issue number10
Publication statusPublished - Oct 1 2014

All Science Journal Classification (ASJC) codes

  • Ophthalmology


Dive into the research topics of 'Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: A multicenter study'. Together they form a unique fingerprint.

Cite this